Summary.-The "chemosensitizing" properties of the radiosensitizer misonidazole (MISO) were examined in 2 tumour systems, murine Lewis lung carcinoma and human pancreatic adenocarcinoma xenografted into immune-suppressed mice, using a soft-agar colony assay to measure tumour-cell survival.
IN A RECENT STUDY (Rose et al., 1980a,b) we reported that concurrent treatment of mice with the cytotoxic drug melphalan and the radiosensitizer misonidazole (MISO) substantially enhanced cell killing in Lewis lung tumour, but with a smaller increase in host-cell killing in 2 normal tissues (CFU-S in marrow and crypt microcolonies in gut). Preliminary experiments also indicated that MISO substantially enhanced the anti-tumour effects of cyclophosphamide and 5-fluorouracil.
We have extended these studies to examine a wider spectrum of anti-cancer drugs in combination with MISO. Two tumour systems were used: murine Lewis lung carcinoma and a human pancreaticcarcinoma xenograft. For most of the studies, tumour response was assessed by clonogenic cell survival, but for the combination of cyclophosphamide and MISO in the Lewis lung carcinoma we have also examined the relationship between tumour-cell survival and tumour-volume response.
METHODS
Mice and tumnours.-C57BL/Cbi and CBA/ Ca mice wrere obtained from the Institute of Cancer Research breeding centre.
Lewis lung carcinoma was passaged by transplantation of tumour brei bilaterally into the gastrocnemius muscles of C57 mice as described by Steel & Adams (1975) . Intramuscular tumours were used for experiments when they reached a weight of 0-2-0-4 g.
Human pancreatic tumour HX32 (Courtenay et al., 1976) was maintained by xenografting into CBA mice which bad been immune-suppressed by thymectomy and whole-body irradiation with cytosine arabinoside protection (Steel et al., 1978 collagenase digestion, into the gastroenemius muscles. Tumours were used for experiments when they were in the range 0-3-0.6 g.
Cytotoxic drugs.-All drugs were administered i.p. Sources of supply, and methods of preparation for injection of melphalan, cyclophosphamide (CY), CCNU, Methyl-CCNU. 5-fluorouracil (FU), bleomycin, vineristine (VCR) and cis-dichlorodiammineplatinum (cis-Pt) have been described previously (Blackett et al., 1975; Stephens & Peacoek, 1978; Rose et al.. 1980b ). VP16-213 was obtained as a solution (concentration 5 mg/ 100 ml) from Sandoz Laboratories (Basle, Switzerland) and was diluted in Dulbecco's phosphate-buffered saline (PBSA) for injection into mice.
Misonidazole (MISO, Roche Products Ltd, Welwyn Garden City, Herts) was prepared for i.p. injection by dissolving the powder in PBSA at a concentration of 25 mg/ml. MISO produces sedation, and precautions wvere taken to prevent MISO-induced hypothermia by keeping mice in a warm environment (,35°C) for about 3 h, as described by Rose et al. (1980b) . In most of the experiments MISO at a dose of 1 mg/g body wt was administered simultaneously with cytotoxic drugs, but in a few cases a lower dose of 0 75 mg/g was used.
Measurement of tnamour growth.-The growth of i.m. Lewis lung tumours was assessed by sequential measurement of tumour-bearing leg diameters by passing unshaved legs through holes of known diameter in a perspex disc. Leg diameters were converted to tumour weight using a calibration curve relating leg diameter to dissected tumour -weight (Steel & Adams. 1975) . Since most tumours did not shrink after drug treatment, tumour-volume responses were determined by measuring the time for tumours to regrow to 4 times their pre-treatment volume (T4 x ) and then calculating growth delay as (median T4 x of treated tumours)-(median T4 x of untreated controls).
Cell survival assay for Lewis lung carcinoma.
-Tumour cell survival was measured about 18 h after drug treatment of tumour-bearing mice as described previously (Courtenay, 1976; . Briefly, for each treatment group, 2 mice each bearing 2 tumours were used. The tumours %were excised, pooled, weighed and chopped finely. They were then trypsinized and the resulting cell suspension was counted in a haemacytometer. We have previously shown that cell suspensions from Lewis lung tumours contain substantial numbers of small host cells Cell survival assay for xenograft HX32. Tumour-cell survival wvas measured about 18 h after drug treatment, using a soft-agar colony assay technique described by Courtenay & Mills (1978 not produce a significant growth delay, but when combined with CY there was a A marked enhancement of the cytotoxic drug effect. MISO, and there is good agreement between-the behaviour of several of the agents which were tested in both tumour systems. For instance, there was substantial enhancement in both tumour models when 2 alkylating agents were tested: melphalan, which is directacting, and CY, which requires enzymatic activation to a cytotoxic form (Sladek, 1973) . Also, there was significant enhancement of 2 nitrosoureas (which alkylate DNA and acylate protein; Wheeler, 1974) in both tumour systems (CCNU in Lewis lung and MeCCNU in HX32). However, cis-Pt, a DNA cross-linking agent (Gale, 1974) , was not enhanced in either of the tumour systems. Of the non-alkylating agents, the mitotic inhibitor VTCR (Creasey, 1974) was greatly enhanced in the Lewis lung tumour system, as also was the antimetabolite FU (Heidelberger, 1974) . However, there was no enhancement of the DNA-fragmenting agents bleomycin (Pietsch, 1 974) or VP16-213, the mechanism of action of which has yet to be elucidated (Arnold, 1979) . We conclude that the mechanism of MISO chemosensitization may be nonspecific, since so many agents with diverse mechanisms of action were enhanced. The failure to detect chemo-enhancement with some of the agents may simply reflect suboptimal drug scheduling, which is at present under investigation.
Although in most experiments cell survival was the endpoint, for CY we also measured growth delay, and found enhancement similar in extent to that seen using the cell-survival assay (i.e. the relationship between cell killing and growth delay with CY is similar whether or not MISO is added-see Fig. 5 ).
In our previous paper (Rose et al., 1980b) we proposed some possible mechanisms to account for the enhancement of melphalan cytotoxicity by MISO; i.e. (1) increased initial concentration of drug available for cytotoxic action, (2) decreased drug inactivation by metabolism or excretion, (3) increased intracellular drug concentration through improved intracellular drug access, (4) a specific potentiating interaction between drug and MISO at the intracellular level, and (5) the independent addition ofMISO cytotoxicity and drug toxicity. The last possibility was discounted on the grounids that we have never been able to demonstrate significant tumour-cell killing by MISO alone in Lewis lung tumours (Pedersen et al., 1979) . In view of the range of drugs which are enhanced, we now conclude that specific potentiating interactions betweeni MISO and drugs at the intracellular level also seems rather unlikely.
The 3 remaining options are all facets of drug pharmacokinetics and are at present under investigation in these laboratories. Preliminary experiments by Dr J. L. Millar, using radiolabelled melphalan, indicate that the clearance of melphalan from the blood is slower in mice treated simultaneously with MISO and melphalan, and using a high-performance liquid chromatography (HPLC) assay for melphalan we also have obtained evidence that the serum half-life of melphalan is increased by concomitant administration of MISO. The significance of this effect is complicated by the fact that the observed enhancement factors differ between tumour and normal tissue (Rose et al., 1980b) . Although slower melphalan clearance might account for a DEF of up to about 1 5 (the maximum value seen in normal tissues) it is difficult to explain the higher DEF (, 2) observed in tumours, without involving additional mechanisms. It is possible that the modest enhancement by MISO in normal tissues may be related to its sedative action. We have reported that the cytotoxicity of melphalan against B16 melanoma and marrow CFU assessed in agar diffusion chambers is substantially enhanced in Saffan-anaesthetized mice , and more recent studies indicate similar enhancement with other cytotoxic drugs and anaesthetics (Peacock et al., 1980) . In view of in vitro experiments which show that MISO specifically enhances the cytotoxicity of several drugs under hypoxic conditions (Stratford et al., 1980) , it is possible that hypoxic cells may mediate the greater drug-enhancing effect seen in vivo in intramuscular tumours. We have recently shown that the DEF for the combination of melphalan and MISO is below 1P5 when Lewis lung carcinoma is treated as small lung colonies (hypoxic fraction -1%) but about 2 when 0 2-0 4g intramuscular tumours (hypoxic fraction 30 %) are used (Spooner, unpublished) .
Further pharmacokinetic measurements with other drugs, cytotoxicity studies in tumours of different types and comparative measurements of the response of various normal tissues are required in order to assess the universality of the effects we have reported, and to establish the magnitude of the therapeutic gain which may be achieved. Studies with lower, more clinically relevant doses of MISO are needed to assess whether the agent is likely to be of value as a chemosensitizer in human cancer.
